Johnson & Johnson New EUA Vaccine

(To join our email list, click here.)
Breaking News
Hallie Levine. 2021. “COVID-19 Update: Your Latest Questions About Johnson & Johnson’s Investigational Vaccine Candidate Answered.” Translated by 1959256290. Content Lab U.S. January 5, 2021. 


Johnson & Johnson rush vaccines to market through their EUA status as they partner with the US government and medical centers worldwide. Funds allocated by their associates exceed $1 billion in research, development, and clinical trials on human subjects as they skip animal tests.

Their primary emphasis, minority populations for experiments. They claim the pathogen attacks colored groups at different rates. Therefore, they prime their target’s immune system with a common cold type of strain, the adenovirus. Throughout the process, the subjects do not understand the consequences of what happens once they encounter a wild variation of the virus.

But this does not matter as they look to release over a billion vaccines by 2021 with an unspecified amount thereafter.

Support Walk In Verse for $5 a month or $50 a year to gain access to all ebooks, reports and special content available to members only. Click here to sign up today and help support independent journalist where we give you the facts without bias.

© 2007-2022 Walk In Verse All rights reserved

Share This

Share on facebook
Share on twitter
Share on telegram
Share on tumblr

Get News & Updates

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top